tiprankstipranks
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Integer Holdings (ITGR), Resmed (RMD) and PTC Therapeutics (PTCT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Integer Holdings (ITGRResearch Report), Resmed (RMDResearch Report) and PTC Therapeutics (PTCTResearch Report).

Integer Holdings (ITGR)

In a report released today, Craig Bijou from Bank of America Securities reiterated a Buy rating on Integer Holdings, with a price target of $135.00. The company’s shares closed last Thursday at $111.15.

According to TipRanks.com, Bijou is a 3-star analyst with an average return of 1.6% and a 43.3% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Merit Medical Systems, and Integra Lifesciences.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Integer Holdings with a $125.29 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Resmed (RMD)

In a report released today, Lyanne Harrison from Bank of America Securities reiterated a Buy rating on Resmed, with a price target of $225.00. The company’s shares closed last Thursday at $183.42.

Harrison has an average return of 1.6% when recommending Resmed.

According to TipRanks.com, Harrison is ranked #7946 out of 8795 analysts.

Currently, the analyst consensus on Resmed is a Strong Buy with an average price target of $215.67, implying a 17.8% upside from current levels. In a report released today, KeyBanc also maintained a Buy rating on the stock with a $238.00 price target.

PTC Therapeutics (PTCT)

Citi analyst David Lebovitz maintained a Sell rating on PTC Therapeutics today and set a price target of $18.00. The company’s shares closed last Thursday at $25.49.

According to TipRanks.com, Lebovitz is a 1-star analyst with an average return of -3.6% and a 42.3% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Crinetics Pharmaceuticals, and Madrigal Pharmaceuticals.

Currently, the analyst consensus on PTC Therapeutics is a Hold with an average price target of $29.22, implying a 18.5% upside from current levels. In a report released today, Goldman Sachs also maintained a Sell rating on the stock with a $18.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ITGR:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles